A novel approach for relapsed/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib

BACKGROUND: Patients with relapsed/refractory acute myeloid leukaemia (AML) with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) have limited treatment options and poor prognosis. Therefore, novel treatment modalities are needed. Since high expression of natural killer group 2 memb...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ke-xin, Wu, Hui-yang, Pan, Wan-ying, Guo, Meng-qi, Qiu, De-zhi, He, Yan-jie, Li, Yu-hua, Yang, Dong-Hua, Huang, Yu-xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896098/
https://www.ncbi.nlm.nih.gov/pubmed/35246156
http://dx.doi.org/10.1186/s12943-022-01541-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896098/
https://www.ncbi.nlm.nih.gov/pubmed/35246156
http://dx.doi.org/10.1186/s12943-022-01541-9

Ejemplares similares